Package Name | Category | A1 | A2 | A3 | A4 | A5 | A6 | S1 | S2 |
---|---|---|---|---|---|---|---|---|---|
CM0100 : BREAST CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-a : combined regimen AC & T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-a-I : Dose Dense AC (Adriamycin/Cyclophosphamide) Followed by Paclitaxel | MEDICAL ONCOLOGY | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 |
CM0100-a-II : Paclitaxel (Preceeded by Dose Dense AC) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
CM0100-b : TC (Doectaxel & Cyclophosphamide) | MEDICAL ONCOLOGY | 5950 | 5950 | 5950 | 5950 | 5950 | 5950 | 5950 | 5950 |
CM0100-c : CMF (Cyclophosphamide/Methotrexate/Fluorouracil) (includes day 1 & day 8) | MEDICAL ONCOLOGY | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 |
CM0100-d : EC (Epirubicin/Cyclophosphamide) | MEDICAL ONCOLOGY | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 |
CM0100-e : FEC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-e-I : FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) followed by Docetaxel or followed by weekly Paclitaxel) | MEDICAL ONCOLOGY | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 |
CM0100-e-II : Docetaxel (Preceeded by FEC/CEF ) | MEDICAL ONCOLOGY | 5450 | 5450 | 5450 | 5450 | 5450 | 5450 | 5450 | 5450 |
CM0100-e-III : Paclitaxel - weekly (Preceeded by FEC/CEF ) | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
CM0100-f : FAC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-f-I : FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) followed by weekly Paclitaxel | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
CM0100-f-II : Paclitaxel - weekly Preceeded by FAC | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
CM0100-g : TAC (Docetaxel/Adriamycin/Cyclophosphamide) | MEDICAL ONCOLOGY | 5550 | 5550 | 5550 | 5550 | 5550 | 5550 | 5550 | 5550 |
CM0100-h : AC followed by T + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-h-I : AC followed by Paclitaxel + Trastuzumab +/- Pertuzumab | MEDICAL ONCOLOGY | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 |
CM0100-h-II : Paclitaxel (Preceeded by AC) | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
CM0100-h-III : Trastuzumab (6mg) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-h-IV : Trastuzumab 4mg (First dose - only) followed by 2mg | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-h-V : Trastuzumab 2mg (Subsequent doses) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
CM0100-i : TCH | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-i-I : TC (Docetaxel/Carboplatin) with Trastuzumab | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0100-i-II : Trastuzumab (6mg) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-i-III : Trastuzumab 4mg (First dose - only) followed by 2mg | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-i-IV : Trastuzumab 2mg (Subsequent doses) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
CM0100-j : AC followed by Docetaxel + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-j-I : AC followed by Docetaxel + Trastuzumab | MEDICAL ONCOLOGY | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 | 2950 |
CM0100-j-II : Docetaxel (preceeded by AC) + Trastuzumab | MEDICAL ONCOLOGY | 5350 | 5350 | 5350 | 5350 | 5350 | 5350 | 5350 | 5350 |
CM0100-j-III : Trastuzumab (6mg) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-j-IV : Trastuzumab 4mg (First dose - only) followed by 2mg | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-j-V : Trastuzumab 2mg (Subsequent doses) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
CM0100-k : Docetaxel + Cyclophosphamide + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-k-I : Docetaxel + Cyclophosphamide with Trastuzumab | MEDICAL ONCOLOGY | 4950 | 4950 | 4950 | 4950 | 4950 | 4950 | 4950 | 4950 |
CM0100-k-II : Trastuzumab (6mg) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-k-III : Trastuzumab 4mg (First dose - only) followed by 2mg | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-k-IV : Trastuzumab 2mg (Subsequent doses) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
CM0100-L : Paclitaxel + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-L-I : Paclitaxel (with Trastuzumab) | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
CM0100-L-II : Trastuzumab (6mg) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-L-III : Trastuzumab 4mg (First dose - only) followed by 2mg | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
CM0100-L-IV : Trastuzumab 2mg (Subsequent doses) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
CM0100-M : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0101 : BLADDER CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0101-a-I : DDMVAC | MEDICAL ONCOLOGY | 3740 | 3740 | 3740 | 3740 | 3740 | 3740 | 3740 | 3740 |
CM0101-a-II : Gemcitabine + cisplatin | MEDICAL ONCOLOGY | 6310 | 6310 | 6310 | 6310 | 6310 | 6310 | 6310 | 6310 |
CM0101-a-III : Cisplatin + methotrexate + vinblastine (CMV) | MEDICAL ONCOLOGY | 2710 | 2710 | 2710 | 2710 | 2710 | 2710 | 2710 | 2710 |
CM0101-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0102 : LUNG CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0102-i : Mesothelioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0102-i-a : Pemetrexed + cisplatin | MEDICAL ONCOLOGY | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 |
CM0102-i-b : Pemetrexed + carboplatin | MEDICAL ONCOLOGY | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 |
CM0102-i-c : Cisplatin & Gemcitabine | MEDICAL ONCOLOGY | 7515 | 7515 | 7515 | 7515 | 7515 | 7515 | 7515 | 7515 |
CM0102-i-d : Vinorelbine | MEDICAL ONCOLOGY | 8950 | 8950 | 8950 | 8950 | 8950 | 8950 | 8950 | 8950 |
CM0102-i-e : Pemetrexed | MEDICAL ONCOLOGY | 14150 | 14150 | 14150 | 14150 | 14150 | 14150 | 14150 | 14150 |
CM0102-i-f : Gemcitabine | MEDICAL ONCOLOGY | 7520 | 7520 | 7520 | 7520 | 7520 | 7520 | 7520 | 7520 |
CM0102-i-g : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0102-ii : NSCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0102-ii-a : Cisplatin & Vinorelbine - (i) | MEDICAL ONCOLOGY | 33550 | 33550 | 33550 | 33550 | 33550 | 33550 | 33550 | 33550 |
CM0102-ii-b : Cisplatin & Vinorelbine - (ii) | MEDICAL ONCOLOGY | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 |
CM0102-ii-c : Cisplatin & Etoposide | MEDICAL ONCOLOGY | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 |
CM0102-ii-d : Cisplatin & Docetaxel | MEDICAL ONCOLOGY | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 |
CM0102-ii-e : Cisplatin & Gemcitabine | MEDICAL ONCOLOGY | 6010 | 6010 | 6010 | 6010 | 6010 | 6010 | 6010 | 6010 |
CM0102-ii-f : Pemetrexed + cisplatin | MEDICAL ONCOLOGY | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 |
CM0102-ii-g : Paclitaxel/Carboplatin | MEDICAL ONCOLOGY | 8050 | 8050 | 8050 | 8050 | 8050 | 8050 | 8050 | 8050 |
CM0102-ii-h : Cisplatin & Etoposide | MEDICAL ONCOLOGY | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 |
CM0102-ii-i : Cisplatin & Vinblastine | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
CM0102-ii-j : Carboplatin + Pemetrexed | MEDICAL ONCOLOGY | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 | 16450 |
CM0102-ii-k : Cisplatin + Pemetrexed | MEDICAL ONCOLOGY | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 |
CM0102-ii-l : Paclitaxel + Carboplatin | MEDICAL ONCOLOGY | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 |
CM0102-ii-m : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0102-iii : LUNG CANCER - NSCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0102-iii-a : Cisplatin & Etoposide | MEDICAL ONCOLOGY | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 |
CM0102-iii-b : Carboplatin & Etoposide | MEDICAL ONCOLOGY | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 |
CM0102-iii-c : Cisplatin + Irinotecan | MEDICAL ONCOLOGY | 5790 | 5790 | 5790 | 5790 | 5790 | 5790 | 5790 | 5790 |
CM0102-iii-d : Cisplatin + Irinotecan | MEDICAL ONCOLOGY | 5670 | 5670 | 5670 | 5670 | 5670 | 5670 | 5670 | 5670 |
CM0102-iii-e : Carboplatin & Irinotecan | MEDICAL ONCOLOGY | 7640 | 7640 | 7640 | 7640 | 7640 | 7640 | 7640 | 7640 |
CM0102-iii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0103-i : ESOPHAGEAL CANCER - Neo Adjuvant | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0103-i-a : Paclitaxel + Carboplatin | MEDICAL ONCOLOGY | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 |
CM0103-i-b : Fluorouracil & Cisplatin | MEDICAL ONCOLOGY | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 |
CM0103-i-c : Fluorouracil & Cisplatin | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0103-i-d : Fluorouracil + Oxaliplatin + Leucovorin | MEDICAL ONCOLOGY | 4590 | 4590 | 4590 | 4590 | 4590 | 4590 | 4590 | 4590 |
CM0103-i-e : Cisplatin + capecitabine | MEDICAL ONCOLOGY | 2450 | 2450 | 2450 | 2450 | 2450 | 2450 | 2450 | 2450 |
CM0103-i-f : Fluorouracil & Oxaliplatin | MEDICAL ONCOLOGY | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 |
CM0103-i-g : Oxaliplatin + capecitabine | MEDICAL ONCOLOGY | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 |
CM0103-i-h : Irinotecan & Cisplatin | MEDICAL ONCOLOGY | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 |
CM0103-i-i : Fluorouracil & Paclitaxel | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
CM0103-i-j : Paclitaxel + capecitabine | MEDICAL ONCOLOGY | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 |
CM0103-i-k : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0103-ii : ESOPHAGEAL CANCER - Peri-Operative | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0103-ii-a : ECF (Epirubicin/Cisplatin/Fluorouracil) | MEDICAL ONCOLOGY | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 |
CM0103-ii-b : EOF (Epirubicin/Cisplatin/Fluorouracil) | MEDICAL ONCOLOGY | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 |
CM0103-ii-c : EOC (Epirubicin/Cisplatin/Fluorouracil) | MEDICAL ONCOLOGY | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 |
CM0103-ii-d : Fluorouracil & Cisplatin | MEDICAL ONCOLOGY | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 |
CM0103-ii-e : Fluorouracil & Cisplatin | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0103-ii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0103-iii : ESOPHAGEAL CANCER - Post-Operative | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0103-iii-a : Fluorouracil + Leucovorin (i) | MEDICAL ONCOLOGY | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 |
CM0103-iii-b : Fluorouracil + Leucovorin (ii) | MEDICAL ONCOLOGY | 8980 | 8980 | 8980 | 8980 | 8980 | 8980 | 8980 | 8980 |
CM0103-iii-c : Capecitabine (i) | MEDICAL ONCOLOGY | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 |
CM0103-iii-d : Capecitabine (ii) | MEDICAL ONCOLOGY | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 |
CM0103-iii-e : Fluorouracil | MEDICAL ONCOLOGY | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 |
CM0103-iii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0103-iv : ESOPHAGEAL CANCER - Definitive | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0103-iv-a : Fluorouracil & Cisplatin (i) | MEDICAL ONCOLOGY | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 |
CM0103-iv-b : Fluorouracil & Cisplatin (ii) | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0103-iv-c : Fluorouracil & Oxaliplatin | MEDICAL ONCOLOGY | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 |
CM0103-iv-d : Cisplatin + capecitabine | MEDICAL ONCOLOGY | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 |
CM0103-iv-e : Oxaliplatin + capecitabine | MEDICAL ONCOLOGY | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 |
CM0103-iv-f : Paclitaxel + Carboplatin | MEDICAL ONCOLOGY | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 |
CM0103-iv-g : Cisplatin with Docetaxel (i) | MEDICAL ONCOLOGY | 8830 | 8830 | 8830 | 8830 | 8830 | 8830 | 8830 | 8830 |
CM0103-iv-h : Cisplatin with Docetaxel (ii) | MEDICAL ONCOLOGY | 2934 | 2934 | 2934 | 2934 | 2934 | 2934 | 2934 | 2934 |
CM0103-iv-i : Cisplatin with Paclitaxel | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
CM0103-iv-j : Irinotecan & Cisplatin | MEDICAL ONCOLOGY | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 | 9676 |
CM0103-iv-k : Fluorouracil & Paclitaxel | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
CM0103-iv-l : Paclitaxel + capecitabine | MEDICAL ONCOLOGY | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 |
CM0103-iv-m : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0104 : GASTRIC CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0104-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0104-i-a : Paclitaxel + Carboplatin | MEDICAL ONCOLOGY | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 | 3230 |
CM0104-i-b : Fluorouracil & Cisplatin (i) | MEDICAL ONCOLOGY | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 | 11980 |
CM0104-i-c : Fluorouracil & Cisplatin (ii) | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0104-i-d : Fluorouracil & Oxaliplatin (i) | MEDICAL ONCOLOGY | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 |
CM0104-i-e : Fluorouracil & Oxaliplatin (ii) | MEDICAL ONCOLOGY | 6030 | 6030 | 6030 | 6030 | 6030 | 6030 | 6030 | 6030 |
CM0104-i-f : Cisplatin + capecitabine | MEDICAL ONCOLOGY | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 | 1950 |
CM0104-i-g : Oxaliplatin + capecitabine | MEDICAL ONCOLOGY | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 | 8880 |
CM0104-i-h : Fluorouracil & Paclitaxel | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
CM0104-i-i : Paclitaxel + capecitabine | MEDICAL ONCOLOGY | 3020 | 3020 | 3020 | 3020 | 3020 | 3020 | 3020 | 3020 |
CM0104-i-j : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0104-ii : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0104-ii-a : ECF (Epirubicin/Cisplatin/Fluorouracil) | MEDICAL ONCOLOGY | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 | 16630 |
CM0104-ii-b : EOF (Epirubicin/ oxaliplatin /Fluorouracil) | MEDICAL ONCOLOGY | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 | 18610 |
CM0104-ii-c : epirubicin + cisplatin + capecitabine | MEDICAL ONCOLOGY | 5808 | 5808 | 5808 | 5808 | 5808 | 5808 | 5808 | 5808 |
CM0104-ii-d : ECF modification: epirubicin + oxaliplatin + capecitabine | MEDICAL ONCOLOGY | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 | 7788 |
CM0104-ii-e : Fluorouracil & Cisplatin | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
CM0104-ii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0104-iii : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction)1 | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0104-iii-a : Fluorouracil + Leucovorin (i) | MEDICAL ONCOLOGY | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 |
CM0104-iii-b : Fluorouracil + Leucovorin (ii) | MEDICAL ONCOLOGY | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 |
CM0104-iii-c : Capecitabine (i) | MEDICAL ONCOLOGY | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 | 3016 |
CM0104-iii-d : Capecitabine (ii) | MEDICAL ONCOLOGY | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 | 1508 |
CM0104-iii-e : Fluorouracil | MEDICAL ONCOLOGY | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 |
CM0104-iii-f : Cisplatin + capecitabine | MEDICAL ONCOLOGY | 3966 | 3966 | 3966 | 3966 | 3966 | 3966 | 3966 | 3966 |
CM0104-iii-h : Oxaliplatin + capecitabine | MEDICAL ONCOLOGY | 5946 | 5946 | 5946 | 5946 | 5946 | 5946 | 5946 | 5946 |
CM0104-iii-i : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0105-i : COLORECTAL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0105-i-a : FOLFOX (Stage - III) | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
CM0105-i-b : CAPEOX (Stage - III) | MEDICAL ONCOLOGY | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 |
CM0105-i-c : FLOX (Stage - III) | MEDICAL ONCOLOGY | 29360 | 29360 | 29360 | 29360 | 29360 | 29360 | 29360 | 29360 |
CM0105-i-d : Capecitabine | MEDICAL ONCOLOGY | 4280 | 4280 | 4280 | 4280 | 4280 | 4280 | 4280 | 4280 |
CM0105-i-e : Fluorouracil + Leucovorin (i) | MEDICAL ONCOLOGY | 23660 | 23660 | 23660 | 23660 | 23660 | 23660 | 23660 | 23660 |
CM0105-i-f : Fluorouracil + Leucovorin (ii) | MEDICAL ONCOLOGY | 5180 | 5180 | 5180 | 5180 | 5180 | 5180 | 5180 | 5180 |
CM0105-i-g : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0105-ii : COLORECTAL CARCINOMA - Concurrent | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0105-ii-a : 5FU with XRT | MEDICAL ONCOLOGY | 3780 | 3780 | 3780 | 3780 | 3780 | 3780 | 3780 | 3780 |
CM0105-ii-b : Fluorouracil + Leucovorin with XRT | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
CM0105-ii-c : Capecitabine with XRT | MEDICAL ONCOLOGY | 1220 | 1220 | 1220 | 1220 | 1220 | 1220 | 1220 | 1220 |
CM0105-ii-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0106-106 : OSTEOSARCOMA/ BONE TUMORS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0106-i-a : Cisplatin + doxorubicin | MEDICAL ONCOLOGY | 5525 | 5525 | 5525 | 5525 | 5525 | 5525 | 5525 | 5525 |
CM0106-i-b-1 : MAP (high-dose methotrexate + cisplatin + doxorubicin) PRE OPERATIVE | MEDICAL ONCOLOGY | 24185 | 24185 | 24185 | 24185 | 24185 | 24185 | 24185 | 24185 |
CM0106-i-b-2 : MAP (high-dose methotrexate + cisplatin + doxorubicin) POST OPERATIVE NECROSIS < 90% | MEDICAL ONCOLOGY | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 |
CM0106-i-b-3 : MAP (high-dose methotrexate + cisplatin + doxorubicin) POST OPERATIVE NECROSIS > 90% | MEDICAL ONCOLOGY | 59025 | 59025 | 59025 | 59025 | 59025 | 59025 | 59025 | 59025 |
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) | MEDICAL ONCOLOGY | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 |
CM0106-i-d : Ifosfamide + cisplatin + epirubicin | MEDICAL ONCOLOGY | 8288 | 8288 | 8288 | 8288 | 8288 | 8288 | 8288 | 8288 |
CM0106-ii : Other bone tumors 1) Chordroma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0106-ii-a : Imatinib | MEDICAL ONCOLOGY | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 |
CM0106-ii-b : Imatinib + cisplatin | MEDICAL ONCOLOGY | 3675 | 3675 | 3675 | 3675 | 3675 | 3675 | 3675 | 3675 |
CM0106-ii-c : Imatinib + sirolimus | MEDICAL ONCOLOGY | 4269 | 4269 | 4269 | 4269 | 4269 | 4269 | 4269 | 4269 |
CM0106-ii-d : Erlotinib | MEDICAL ONCOLOGY | 2124 | 2124 | 2124 | 2124 | 2124 | 2124 | 2124 | 2124 |
CM0106-ii-e : Sunitinib | MEDICAL ONCOLOGY | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 |
CM0106-iii : 2)Giant Cell Tumor of Bone | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0106-iii-a : Denosumab | MEDICAL ONCOLOGY | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 |
CM0106-iii-b : Interferon alfa | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
CM0106-iii-c : Peginterferon | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
CM0106-iv : 3) Mesenchymal Chordosarcoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0106-iv-a : VAC and IE cycles | MEDICAL ONCOLOGY | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 |
CM0106-iv-b : VAIA | MEDICAL ONCOLOGY | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 |
CM0106-v : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0107 : WILMS TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0107-a : Vincristine & Actinomycin D | MEDICAL ONCOLOGY | 19365 | 19365 | 19365 | 19365 | 19365 | 19365 | 19365 | 19365 |
CM0107-b : Dactinomycin, Vincristine & Adriamycin | MEDICAL ONCOLOGY | 23175 | 23175 | 23175 | 23175 | 23175 | 23175 | 23175 | 23175 |
CM0107-c : Adriamycin, Cyclophosphamide, Etoposide, Vincristine | MEDICAL ONCOLOGY | 53670 | 53670 | 53670 | 53670 | 53670 | 53670 | 53670 | 53670 |
CM0107-d : Cyclophosphamide, Etoposide, Carboplatin | MEDICAL ONCOLOGY | 84440 | 84440 | 84440 | 84440 | 84440 | 84440 | 84440 | 84440 |
CM0107-e : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0108 : HEPATOBLASTOMA- OPERABLE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0108-a : PLADO - Cisplatin + Doxorubicin | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
CM0108-b : Cisplatin + Vincristine +5FU | MEDICAL ONCOLOGY | 2360 | 2360 | 2360 | 2360 | 2360 | 2360 | 2360 | 2360 |
CM0108-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0109 : HEPATOCELLULAR CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0109-a : Sorafenib | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
CM0109-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0110A : VINCRITINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN | MEDICAL ONCOLOGY | 7940 | 7940 | 7940 | 7940 | 7940 | 7940 | 7940 | 7940 |
CM0110B : CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
CM0110C : Cisplatin & Etoposide | MEDICAL ONCOLOGY | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 | 4880 |
CM0110D : Carboplatin & Etoposide | MEDICAL ONCOLOGY | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 |
CM0110E : For Stage IV Palliative Chemotherapy only | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0110F : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0111 : RETINOBLASTOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0111-a : Melphalan - Intra-arterial | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
CM0111-b : Carboplatin - Intra-arterial | MEDICAL ONCOLOGY | 8890 | 8890 | 8890 | 8890 | 8890 | 8890 | 8890 | 8890 |
CM0111-c : Topotecan - Intra-arterial | MEDICAL ONCOLOGY | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 |
CM0111-d : Methotrexate - Intra-arterial | MEDICAL ONCOLOGY | 8550 | 8550 | 8550 | 8550 | 8550 | 8550 | 8550 | 8550 |
CM0111-e : Carboplatin - Peri Ocular | MEDICAL ONCOLOGY | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 |
CM0111-f : Topotecan - Peri Ocular | MEDICAL ONCOLOGY | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 |
CM0111-g : Melphalan - Intra-vitreal | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
CM0111-h : Carboplatin - Intra-vitreal | MEDICAL ONCOLOGY | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 | 1890 |
CM0111-i : Methotrexate - Intra-vitreal | MEDICAL ONCOLOGY | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 |
CM0111-j : Carboplatin + Etoposide + Vincristine | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
CM0111-k : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0112 : LANGERHANS CELL HISTIOCYTOSIS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0112-a : Prednisolone and Vinblastine - 1 | MEDICAL ONCOLOGY | 6059 | 6059 | 6059 | 6059 | 6059 | 6059 | 6059 | 6059 |
CM0112-b : Prednisolone and Vinblastine - 2 | MEDICAL ONCOLOGY | 6734 | 6734 | 6734 | 6734 | 6734 | 6734 | 6734 | 6734 |
CM0112-c : Prednisolone and Vinblastine - continuation | MEDICAL ONCOLOGY | 1720 | 1720 | 1720 | 1720 | 1720 | 1720 | 1720 | 1720 |
CM0112-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0113 : RHABDOMYOSARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0113-a : VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) | MEDICAL ONCOLOGY | 3755 | 3755 | 3755 | 3755 | 3755 | 3755 | 3755 | 3755 |
CM0113-b : IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) | MEDICAL ONCOLOGY | 5551 | 5551 | 5551 | 5551 | 5551 | 5551 | 5551 | 5551 |
CM0113-c : IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) | MEDICAL ONCOLOGY | 5494 | 5494 | 5494 | 5494 | 5494 | 5494 | 5494 | 5494 |
CM0113-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0114 : EWINGS SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0114-i : Induction Treatment I | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0114-i-a : VIDE | MEDICAL ONCOLOGY | 8235 | 8235 | 8235 | 8235 | 8235 | 8235 | 8235 | 8235 |
CM0114-i-b : VAC/IE | MEDICAL ONCOLOGY | 6390 | 6390 | 6390 | 6390 | 6390 | 6390 | 6390 | 6390 |
CM0114-i-c : VAIA - 4 day Regimen | MEDICAL ONCOLOGY | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 | 7560 |
CM0114-i-d : VAIA - 24 day Regimen | MEDICAL ONCOLOGY | 17660 | 17660 | 17660 | 17660 | 17660 | 17660 | 17660 | 17660 |
CM0114-ii : Maintenance Treatment | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0114-ii-a : Etoposide/Ifosfamide | MEDICAL ONCOLOGY | 8190 | 8190 | 8190 | 8190 | 8190 | 8190 | 8190 | 8190 |
CM0114-iii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0116 : CERVICAL CANCER | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
CM0116-a : CISPLATIN | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
CM0116-b : Cisplatin & 5FU with RT | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
CM0116-c : Cisplatin & 5FU | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
CM0116-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0117 : VULVAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0117-a : Cisplatin | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
CM0117-b : Cisplatin + 5FU | MEDICAL ONCOLOGY | 8620 | 8620 | 8620 | 8620 | 8620 | 8620 | 8620 | 8620 |
CM0117-c : 5-FU + Mitomycin | MEDICAL ONCOLOGY | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 |
CM0117-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0118 : VAGINAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0118-a : Cisplatin | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
CM0118-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0119 : OVARIAN CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0119-a : Paclitaxel + Cisplatin | MEDICAL ONCOLOGY | 8750 | 8750 | 8750 | 8750 | 8750 | 8750 | 8750 | 8750 |
CM0119-b : Paclitaxel + Carboplatin | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
CM0119-c : Docetaxel + Carboplatin | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
CM0119-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0121 : OVARY- GERM CELL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0121-a : BEP (Bleomycin + Etoposide + Cisplatin) | MEDICAL ONCOLOGY | 10780 | 10780 | 10780 | 10780 | 10780 | 10780 | 10780 | 10780 |
CM0121-b : EP ( Etoposide + Carboplatin) | MEDICAL ONCOLOGY | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 | 6430 |
CM0121-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0122 : GESTATIONAL TROPHOBLAST DISEASES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0122-a : Methotrexate (5 days regimen) | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0122-b : Methotrexate (8-day alternating regimen) | MEDICAL ONCOLOGY | 2860 | 2860 | 2860 | 2860 | 2860 | 2860 | 2860 | 2860 |
CM0122-c : Methotrexate + Folinic Acid | MEDICAL ONCOLOGY | 1980 | 1980 | 1980 | 1980 | 1980 | 1980 | 1980 | 1980 |
CM0122-d : Methotrexate - Weekly | MEDICAL ONCOLOGY | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 |
CM0122-e : Act-D | MEDICAL ONCOLOGY | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 |
CM0122-f : Actinomycin | MEDICAL ONCOLOGY | 2190 | 2190 | 2190 | 2190 | 2190 | 2190 | 2190 | 2190 |
CM0122-g : EMA-CO (complete) | MEDICAL ONCOLOGY | 6360 | 6360 | 6360 | 6360 | 6360 | 6360 | 6360 | 6360 |
CM0122-h : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0123 : TESTICULAR CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0123-a : EP | MEDICAL ONCOLOGY | 5360 | 5360 | 5360 | 5360 | 5360 | 5360 | 5360 | 5360 |
CM0123-b : BEP | MEDICAL ONCOLOGY | 9980 | 9980 | 9980 | 9980 | 9980 | 9980 | 9980 | 9980 |
CM0123-c : VIP | MEDICAL ONCOLOGY | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 | 6250 |
CM0123-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0124 : PROSTATE CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0124-a : Docetaxel + prednisone | MEDICAL ONCOLOGY | 3515 | 3515 | 3515 | 3515 | 3515 | 3515 | 3515 | 3515 |
CM0124-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0125 : FEBRILE NEUTROPENIA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0125-a : First-line monotherapy | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
CM0125-b : Second-line dual therapy | MEDICAL ONCOLOGY | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 |
CM0125-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0126 : THYROID CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0126-a : sorafenib | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
CM0126-b : sunitinib | MEDICAL ONCOLOGY | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 |
CM0126-c : Small molecule kinase inhibitor | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
CM0126-d : Doxorubicin | MEDICAL ONCOLOGY | 4350 | 4350 | 4350 | 4350 | 4350 | 4350 | 4350 | 4350 |
CM0126-e : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0127 : THYMOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0127-a : CAP | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
CM0127-b : CAPP | MEDICAL ONCOLOGY | 6771 | 6771 | 6771 | 6771 | 6771 | 6771 | 6771 | 6771 |
CM0127-c : ADOC | MEDICAL ONCOLOGY | 2870 | 2870 | 2870 | 2870 | 2870 | 2870 | 2870 | 2870 |
CM0127-d : PE | MEDICAL ONCOLOGY | 5080 | 5080 | 5080 | 5080 | 5080 | 5080 | 5080 | 5080 |
CM0127-e : VIP | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
CM0127-f : Carboplatin+paclitaxel | MEDICAL ONCOLOGY | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 |
CM0127-g : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0128 : BRAIN CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-i : Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-i-a : Combination PCV (lomustine + procarbazine + vincristine) | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
CM0128-i-b : Temozolomide (7 weeks) | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
CM0128-i-c : Temozolomide monthly 5-day course | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-i-d : Temozolomide (3 weeks) | MEDICAL ONCOLOGY | 3310 | 3310 | 3310 | 3310 | 3310 | 3310 | 3310 | 3310 |
CM0128-ii : Systemic Therapy for Anaplastic Gliomas | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-ii-a : Temozolomide monthly 5-day course | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-ii-b : PCV with deferred RT (lomustine + procarbazine + vincristine) | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
CM0128-ii-c : Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide | MEDICAL ONCOLOGY | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 |
CM0128-ii-d : Adjuvant Temozolomide | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-ii-e : PCV for 1p19q co-deleted (with Radiotherapy) | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
CM0128-iii : Systemic Therapy for Glioblastoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-iii-a : Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide | MEDICAL ONCOLOGY | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 | 14230 |
CM0128-iii-b : Adjuvant Temozolomide | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-iii-c : Temozolomide (post RT) | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-iii-d : Temozolomide (200mg) with standard RT | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0128-iv : Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-iv-a : Vincristine + cisplatin + lomustine | MEDICAL ONCOLOGY | 4320 | 4320 | 4320 | 4320 | 4320 | 4320 | 4320 | 4320 |
CM0128-iv-b : Vincristine + cisplatin + cyclophosphamide | MEDICAL ONCOLOGY | 5480 | 5480 | 5480 | 5480 | 5480 | 5480 | 5480 | 5480 |
CM0128-v : Primary CNS Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-a : High dose methotrexate combined with the following plus radiation therapy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-a-1 : High dose Methotrexate + Cytarabine | MEDICAL ONCOLOGY | 6520 | 6520 | 6520 | 6520 | 6520 | 6520 | 6520 | 6520 |
CM0128-v-a-2 : High dose Methotrexate + leucovorin + Ifosfamide + mesna | MEDICAL ONCOLOGY | 9405 | 9405 | 9405 | 9405 | 9405 | 9405 | 9405 | 9405 |
CM0128-v-b : High dose methotrexate combined with the following plus radiation therapy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-b-1 : Rituximab + MTX + vincristine +procarbazine | MEDICAL ONCOLOGY | 41890 | 41890 | 41890 | 41890 | 41890 | 41890 | 41890 | 41890 |
CM0128-v-c : High dose methotrexate (MTX 8.0mg/m2) + chemotherapy with or without monoclonal antibody | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-c-1 : High dose methotrexate Induction | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
CM0128-v-c-2 : High dose methotrexate Consolidation | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
CM0128-v-c-3-i : High dose methotrexate Maintanance 1-4 cycles | MEDICAL ONCOLOGY | 25530 | 25530 | 25530 | 25530 | 25530 | 25530 | 25530 | 25530 |
CM0128-v-c-3-ii : High dose methotrexate Maintanance 5-11 cycles | MEDICAL ONCOLOGY | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 | 1550 |
CM0128-v-d : Rituximab + Temozolomide regimen | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-d-1 : Rituximab + Temozolomide regimen - Induction | MEDICAL ONCOLOGY | 26580 | 26580 | 26580 | 26580 | 26580 | 26580 | 26580 | 26580 |
CM0128-v-d-2 : Rituximab + Temozolomide regimen - Maintanance | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
CM0128-v-e : Meningioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0128-v-e-1 : Interferon-alfa | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
CM0128-v-e-2 : Somatostatin analog | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
CM0128-v-e-3 : Sunitinib | MEDICAL ONCOLOGY | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 |
CM0129 : HEAD AND NECK CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0129-i : Squamous Cell Cancers | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0129-i-a : HIgh Dose Cisplatin | MEDICAL ONCOLOGY | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 |
CM0129-i-b : Carboplatin + infusional 5-FU | MEDICAL ONCOLOGY | 4760 | 4760 | 4760 | 4760 | 4760 | 4760 | 4760 | 4760 |
CM0129-i-c : 5-FU + hydroxyurea | MEDICAL ONCOLOGY | 2220 | 2220 | 2220 | 2220 | 2220 | 2220 | 2220 | 2220 |
CM0129-i-d : Cisplatin + paclitaxel | MEDICAL ONCOLOGY | 3350 | 3350 | 3350 | 3350 | 3350 | 3350 | 3350 | 3350 |
CM0129-i-e : Cisplatin + infusional 5-FU | MEDICAL ONCOLOGY | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 |
CM0129-i-f : Carboplatin + paclitaxel | MEDICAL ONCOLOGY | 3480 | 3480 | 3480 | 3480 | 3480 | 3480 | 3480 | 3480 |
CM0129-i-g : Weekly cisplatin | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
CM0129-i-h : Cisplatin (For high risk oropharyngeal carcinoma) | MEDICAL ONCOLOGY | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 |
CM0129-i-i : Docetaxel + cisplatin + 5-FU | MEDICAL ONCOLOGY | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 |
CM0129-i-j : Paclitaxel + cisplatin+ infusional 5-FU | MEDICAL ONCOLOGY | 7850 | 7850 | 7850 | 7850 | 7850 | 7850 | 7850 | 7850 |
CM0129-ii : Nasopharynx Cancer | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0129-ii-a : Concurrent Cisplatin followed by concurrent Cisplatin +5FU | MEDICAL ONCOLOGY | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 | 8450 |
CM0129-ii-a-1 : Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) | MEDICAL ONCOLOGY | 1250 | 1250 | 1250 | 1250 | 1250 | 1250 | 1250 | 1250 |
CM0129-ii-a-2 : concurrent Cisplatin +5FU Preceeded by (Concurrent Cisplatin ) | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
CM0129-ii-b : Concurrent Carboplatin followed by concurrent Carboplatin +5FU | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0129-ii-b-1 : Concurrent Carboplatin (followed by concurrent Carboplatin +5FU) | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
CM0129-ii-b-2 : concurrent Carboplatin +5FU Preceeded by (Concurrent Carboplatin ) | MEDICAL ONCOLOGY | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 | 13900 |
CM0129-ii-c : Concurrent Cisplatin | MEDICAL ONCOLOGY | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 |
CM0129-ii-d : Docetaxel + cisplatin + 5-FU | MEDICAL ONCOLOGY | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 | 6620 |
CM0129-ii-d-1 : Docetaxel + cisplatin + 5-FU followed by Cisplatin after 3 cycles | MEDICAL ONCOLOGY | 6370 | 6370 | 6370 | 6370 | 6370 | 6370 | 6370 | 6370 |
CM0129-ii-d-2 : Cisplatin - weekly Preceded by 3 cycles of Docetaxel + 5-FU | MEDICAL ONCOLOGY | 2250 | 2250 | 2250 | 2250 | 2250 | 2250 | 2250 | 2250 |
CM0129-ii-e : Docetaxel + cisplatin | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0129-ii-e-1 : Docetaxel + cisplatin followed by Cisplatin after 2 cycles | MEDICAL ONCOLOGY | 3320 | 3320 | 3320 | 3320 | 3320 | 3320 | 3320 | 3320 |
CM0129-ii-e-2 : Cisplatin - weekly Preceded by 2 cycles of Docetaxel + cisplatin | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
CM0129-ii-f : Cisplatin + 5-FU | MEDICAL ONCOLOGY | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 | 5050 |
CM0129-iii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0130 : RENAL CELL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0130-a : Pazopanib | MEDICAL ONCOLOGY | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 |
CM0130-b : Sunitinib | MEDICAL ONCOLOGY | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 |
CM0130-c : Sorafenib | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
CM0130-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0131 : UNKNOWN PRIMARY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0131-i : Adenocarcinoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0131-i-a : Paclitaxel + carboplatin + etoposide | MEDICAL ONCOLOGY | 7950 | 7950 | 7950 | 7950 | 7950 | 7950 | 7950 | 7950 |
CM0131-i-b : Paclitaxel + carboplatin | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
CM0131-i-c : Docetaxel + carboplatin | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
CM0131-i-d : Gemcitabine + cisplatin | MEDICAL ONCOLOGY | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 |
CM0131-i-e : Gemcitabine + docetaxel | MEDICAL ONCOLOGY | 5720 | 5720 | 5720 | 5720 | 5720 | 5720 | 5720 | 5720 |
CM0131-i-f : Gemcitabine + irinotecan | MEDICAL ONCOLOGY | 5560 | 5560 | 5560 | 5560 | 5560 | 5560 | 5560 | 5560 |
CM0131-ii : Squamous cell carcinoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0131-ii-a : Paclitaxel + cisplatin + 5-FU | MEDICAL ONCOLOGY | 6170 | 6170 | 6170 | 6170 | 6170 | 6170 | 6170 | 6170 |
CM0131-ii-b : Docetaxel + cisplatin + 5-FU | MEDICAL ONCOLOGY | 6770 | 6770 | 6770 | 6770 | 6770 | 6770 | 6770 | 6770 |
CM0131-iii : Neuroendocrine tumors | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0131-iii-b : Etoposide + cisplatin | MEDICAL ONCOLOGY | 4980 | 4980 | 4980 | 4980 | 4980 | 4980 | 4980 | 4980 |
CM0131-iv : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0132 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0132-a : Gemcitabine + cisplatin | MEDICAL ONCOLOGY | 3697 | 3697 | 3697 | 3697 | 3697 | 3697 | 3697 | 3697 |
CM0132-b : 5-FU | MEDICAL ONCOLOGY | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 |
CM0132-c : Capecitabine | MEDICAL ONCOLOGY | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 |
CM0132-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0133 : PANCREAS CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0133-i : Patients with resectable pancreatic cancer: Locally Advanced | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0133-i-a : Gemcitabine | MEDICAL ONCOLOGY | 6515 | 6515 | 6515 | 6515 | 6515 | 6515 | 6515 | 6515 |
CM0133-ii : Adjuvant chemotherapy and chemoradiation: | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0133-ii-a : 5-FU + Leucovorin | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
CM0133-ii-b : Gemcitabine & 5FU | MEDICAL ONCOLOGY | 6695 | 6695 | 6695 | 6695 | 6695 | 6695 | 6695 | 6695 |
CM0133-ii-c : Continuous infusion 5-FU (with Radiation) | MEDICAL ONCOLOGY | 20620 | 20620 | 20620 | 20620 | 20620 | 20620 | 20620 | 20620 |
CM0133-iii : Neoadjuvant therapy: | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0133-iii-a : Capecitabine | MEDICAL ONCOLOGY | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 | 3520 |
CM0133-iv : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0134 : PERI AMPULLARY CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0134-a : 5-FU | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
CM0134-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0135 : NEURO ENDOCRINE CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0135-a : All NECs are covered under Organ Cancers. If uncovered Unlisted only. | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0135-b : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0136 : SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0136-i : Gastrointestinal Stromal Tumor - GIST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0136-i-a : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0136-ii : SOFT TISSUE SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0136-ii-a : Doxorubicin + dacarbazine (AD) | MEDICAL ONCOLOGY | 11420 | 11420 | 11420 | 11420 | 11420 | 11420 | 11420 | 11420 |
CM0136-ii-b : Doxorubicin + ifosfamide + mesna | MEDICAL ONCOLOGY | 9166 | 9166 | 9166 | 9166 | 9166 | 9166 | 9166 | 9166 |
CM0136-ii-c : Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) | MEDICAL ONCOLOGY | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 |
CM0136-ii-d : Ifosfamide + epirubicin + mesna | MEDICAL ONCOLOGY | 12770 | 12770 | 12770 | 12770 | 12770 | 12770 | 12770 | 12770 |
CM0136-ii-e : Gemcitabine + docetaxel | MEDICAL ONCOLOGY | 5060 | 5060 | 5060 | 5060 | 5060 | 5060 | 5060 | 5060 |
CM0136-ii-f : Gemcitabine + vinorelbine | MEDICAL ONCOLOGY | 14640 | 14640 | 14640 | 14640 | 14640 | 14640 | 14640 | 14640 |
CM0136-ii-g : Gemcitabine + dacarbazine | MEDICAL ONCOLOGY | 3255 | 3255 | 3255 | 3255 | 3255 | 3255 | 3255 | 3255 |
CM0136-ii-h : Doxorubicin | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
CM0136-ii-i : Ifosfamide | MEDICAL ONCOLOGY | 9956 | 9956 | 9956 | 9956 | 9956 | 9956 | 9956 | 9956 |
CM0136-ii-j : Ifosfamide | MEDICAL ONCOLOGY | 4855 | 4855 | 4855 | 4855 | 4855 | 4855 | 4855 | 4855 |
CM0136-ii-k : Epirubicin | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
CM0136-ii-l : Gemcitabine | MEDICAL ONCOLOGY | 3505 | 3505 | 3505 | 3505 | 3505 | 3505 | 3505 | 3505 |
CM0136-ii-m : Dacarbazine (i) | MEDICAL ONCOLOGY | 6175 | 6175 | 6175 | 6175 | 6175 | 6175 | 6175 | 6175 |
CM0136-ii-n : Dacarbazine (ii) | MEDICAL ONCOLOGY | 2350 | 2350 | 2350 | 2350 | 2350 | 2350 | 2350 | 2350 |
CM0136-ii-o : Liposomal doxorubicin | MEDICAL ONCOLOGY | 7860 | 7860 | 7860 | 7860 | 7860 | 7860 | 7860 | 7860 |
CM0136-ii-p : Temozolomide | MEDICAL ONCOLOGY | 4190 | 4190 | 4190 | 4190 | 4190 | 4190 | 4190 | 4190 |
CM0136-iii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0137 : PRIMITIVE NEURO ECTODERMAL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0137-a : Weekly vincristine | MEDICAL ONCOLOGY | 1640 | 1640 | 1640 | 1640 | 1640 | 1640 | 1640 | 1640 |
CM0137-b : Vincristine + cisplatin + lomustine | MEDICAL ONCOLOGY | 4360 | 4360 | 4360 | 4360 | 4360 | 4360 | 4360 | 4360 |
CM0137-c : Vincristine + cisplatin + cyclophosphamide | MEDICAL ONCOLOGY | 7570 | 7570 | 7570 | 7570 | 7570 | 7570 | 7570 | 7570 |
CM0137-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0137-vi : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy (Maximum) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0139 : ANAL CANAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0139-a : 5-FU + Mitomycin | MEDICAL ONCOLOGY | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 | 11360 |
CM0139-b : Capecitabine + Mitomycin (i) | MEDICAL ONCOLOGY | 8080 | 8080 | 8080 | 8080 | 8080 | 8080 | 8080 | 8080 |
CM0139-c : Capecitabine + Mitomycin (ii) | MEDICAL ONCOLOGY | 6765 | 6765 | 6765 | 6765 | 6765 | 6765 | 6765 | 6765 |
CM0139-d : Cisplatin + 5-FU | MEDICAL ONCOLOGY | 6650 | 6650 | 6650 | 6650 | 6650 | 6650 | 6650 | 6650 |
CM0139-e : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A : All Leukemia ( Chemotheraphy) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-I : Chronic Myeloid Leukemia (CML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-I-i-a : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0952A-I-i-b : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
CM0952A-I-ii : Blast phase-Lymphoid ALL Type Induction + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-I-ii-a : Induction | MEDICAL ONCOLOGY | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 |
CM0952A-I-ii-b : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0952A-I-ii-c : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
CM0952A-I-iii : Blast phase-myeloid AML Type Induction + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine | MEDICAL ONCOLOGY | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 |
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 |
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 |
CM0952A-I-iii-f : Idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
CM0952A-I-iii-g : mitoxantrone + Cytarabine | MEDICAL ONCOLOGY | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 |
CM0952A-I-iii-h : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0952A-I-iii-i : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
CM0952A-I-iii-ii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-I-iii-iii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-II : Acute Myeloid Leukemia (AML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-II-a : Daunorubicin + Cytarabine 1 | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
CM0952A-II-b : Idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
CM0952A-II-c : Daunorubicin + Cytarabine 2 | MEDICAL ONCOLOGY | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 |
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 |
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 |
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
CM0952A-II-g : idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
CM0952A-II-h : mitoxantrone + Cytarabine | MEDICAL ONCOLOGY | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 |
CM0952A-II-i : Cytarabine | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
CM0952A-II-j : Decitabine | MEDICAL ONCOLOGY | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 |
CM0952A-II-k : azacytidine | MEDICAL ONCOLOGY | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 |
CM0952A-II-l : Hydroxyurea | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
CM0952A-II-m : Cytarabine - High Dose | MEDICAL ONCOLOGY | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 |
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf | MEDICAL ONCOLOGY | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 |
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf | MEDICAL ONCOLOGY | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 |
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf | MEDICAL ONCOLOGY | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 |
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone | MEDICAL ONCOLOGY | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 |
CM0952A-II-r : Cytarabine SC | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
CM0952A-II-s : azacytidine | MEDICAL ONCOLOGY | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 |
CM0952A-II-t : Decitabine | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0952A-II-u : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-III : Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 | MEDICAL ONCOLOGY | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 |
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 | MEDICAL ONCOLOGY | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 |
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 | MEDICAL ONCOLOGY | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 |
CM0952A-III-a-iv : Maintanance - Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: | MEDICAL ONCOLOGY | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 |
CM0952A-III-c : Chlorambucil | MEDICAL ONCOLOGY | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 |
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) | MEDICAL ONCOLOGY | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 |
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) | MEDICAL ONCOLOGY | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 |
CM0952A-III-f : Fludarabine + rituximab (FR) | MEDICAL ONCOLOGY | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 |
CM0952A-III-g : Alemtuzumab + rituximab | MEDICAL ONCOLOGY | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 |
CM0952A-III-h : Alemtuzumab without rituximab | MEDICAL ONCOLOGY | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 |
CM0952A-III-i : High-dose methylprednisolone + rituximab | MEDICAL ONCOLOGY | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 |
CM0952A-III-j : High-dose methylprednisolone | MEDICAL ONCOLOGY | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 |
CM0952A-III-k : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-IV : Acute Lymphoblastic Leukemia (ALL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-IV-i : Ph(+) AYA (Age 15-39 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE | MEDICAL ONCOLOGY | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 |
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 | MEDICAL ONCOLOGY | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 |
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 | MEDICAL ONCOLOGY | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 |
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION | MEDICAL ONCOLOGY | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 |
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION | MEDICAL ONCOLOGY | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 |
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) | MEDICAL ONCOLOGY | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 |
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) | MEDICAL ONCOLOGY | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 |
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 |
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 |
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 |
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | MEDICAL ONCOLOGY | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 |
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | MEDICAL ONCOLOGY | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 |
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | MEDICAL ONCOLOGY | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 |
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | MEDICAL ONCOLOGY | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 |
CM0952A-IV-i-c-5 : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0952A-IV-i-c-6 : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
CM0952A-IV-i-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-IV-ii : Ph(+) AYA (Age > 40 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 |
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 |
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 |
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | MEDICAL ONCOLOGY | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 |
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | MEDICAL ONCOLOGY | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 |
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | MEDICAL ONCOLOGY | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 |
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | MEDICAL ONCOLOGY | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 |
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | MEDICAL ONCOLOGY | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 |
CM0952A-IV-ii-b-5 : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
CM0952A-IV-ii-b-6 : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
CM0952A-IV-ii-c : Corticosteroids + TKIs | MEDICAL ONCOLOGY | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 |
CM0952A-IV-ii-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-IV-iii : Ph(-) AYA (Age 15-39 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION | MEDICAL ONCOLOGY | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 |
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE | MEDICAL ONCOLOGY | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 |
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION | MEDICAL ONCOLOGY | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 |
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) | MEDICAL ONCOLOGY | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 |
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) | MEDICAL ONCOLOGY | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 |
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance | MEDICAL ONCOLOGY | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 |
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: | MEDICAL ONCOLOGY | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 |
CM0952A-IV-iii-v : CCG-1961 | MEDICAL ONCOLOGY | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 |
CM0952A-IV-iii-vi : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0952A-IV-iv : Ph(-) AYA (Age > 40 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION | MEDICAL ONCOLOGY | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 |
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION | MEDICAL ONCOLOGY | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 |
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 | MEDICAL ONCOLOGY | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 |
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 | MEDICAL ONCOLOGY | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 |
CM0952A-IV-iii-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A : All Lymphoma Chemotheraphy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-I : Hodgkins Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-I-a : ABVD | MEDICAL ONCOLOGY | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 |
CM0953A-I-b : Escalated BEACOPP | MEDICAL ONCOLOGY | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 |
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) | MEDICAL ONCOLOGY | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 |
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD | MEDICAL ONCOLOGY | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 |
CM0953A-I-d-ii : ABVD | MEDICAL ONCOLOGY | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 |
CM0953A-I-e-i : CHOP + Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-I-e-ii : CHOP | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-I-f-i : CVP +/- Rituximab | MEDICAL ONCOLOGY | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 |
CM0953A-I-f-ii : CVP | MEDICAL ONCOLOGY | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 |
CM0953A-I-g : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0953A-I-h : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-II : Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-II-a : Bortezomib + dexamethasone | MEDICAL ONCOLOGY | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 |
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-II-c : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone | MEDICAL ONCOLOGY | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 |
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone | MEDICAL ONCOLOGY | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 |
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) | MEDICAL ONCOLOGY | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 |
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 | MEDICAL ONCOLOGY | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 |
CM0953A-II-g-i : Bendamustine with or without rituximab | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
CM0953A-II-g-ii : Bendamustine - rituximab | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
CM0953A-II-h-i : Cladribine with or without rituximab | MEDICAL ONCOLOGY | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 |
CM0953A-II-h-ii : Cladribine - rituximab | MEDICAL ONCOLOGY | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 |
CM0953A-II-i : Bendamustine | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
CM0953A-II-j : Chlorambucil | MEDICAL ONCOLOGY | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 |
CM0953A-II-k : Fludarabine | MEDICAL ONCOLOGY | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 |
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) | MEDICAL ONCOLOGY | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 |
CM0953A-II-m : Alemtuzumab | MEDICAL ONCOLOGY | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 |
CM0953A-II-n : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III : NON HODGKINS LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-i : BURKITT LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: | MEDICAL ONCOLOGY | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 |
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: | MEDICAL ONCOLOGY | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 |
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: | MEDICAL ONCOLOGY | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 |
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: | MEDICAL ONCOLOGY | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 |
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) | MEDICAL ONCOLOGY | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 |
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) | MEDICAL ONCOLOGY | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 |
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) | MEDICAL ONCOLOGY | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 |
CM0953A-III-i-i : HDAC + Rituximab | MEDICAL ONCOLOGY | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 |
CM0953A-III-i-ii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-ii : NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) | MEDICAL ONCOLOGY | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 |
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-III-ii-c : CHOEP | MEDICAL ONCOLOGY | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 |
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) | MEDICAL ONCOLOGY | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 |
CM0953A-III-ii-e : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-iii : DIFFUSE LARGE B CELL LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-III-iii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-iv : AIDS-Related B-Cell Lymphomas | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-III-iv-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-v : Primary Cutaneous Marginal Zone or Follicle Center Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-III-v-b : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0953A-III-v-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-vi : Follicular Lymphoma (Grade 1-2) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) | MEDICAL ONCOLOGY | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 |
CM0953A-III-vi-d : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
CM0953A-III-vi-e : Lenalidomide + Rituximab | MEDICAL ONCOLOGY | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 |
CM0953A-III-vi-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0953A-III-vii : Extranodal NK/T-Cell Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0953A-III-vii-a : SMILE | MEDICAL ONCOLOGY | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 |
CM0953A-III-vii-b : DeVIC +RT | MEDICAL ONCOLOGY | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 |
CM0953A-III-vii-c : VIPID | MEDICAL ONCOLOGY | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 |
CM0953A-III-vii-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
CM0954 : Myelodysplastic Syndromes Treatment Regimens | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0954-i : Symptomatic Anemia With del(5q) with or without Other Cytogenetic Abnormalities | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0954-i-a : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
CM0954-ii : Symptomatic Anemia Without del(5q) and Serum Erythropoietin =500mU/mL | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0954-ii-a-1 : rHu-Epo with or without G-CSF | MEDICAL ONCOLOGY | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 |
CM0954-ii-a-2 : rHu-Epo (-) G-CSF | MEDICAL ONCOLOGY | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 |
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF | MEDICAL ONCOLOGY | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 |
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF | MEDICAL ONCOLOGY | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 |
CM0954-iii : Symptomatic Anemia Without del(5q), Serum Erythropoietin >500mU/mL, Unlikely to Respond to IST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0954-iii-a-1 : Decitabine (15mg/m2) | MEDICAL ONCOLOGY | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 |
CM0954-iii-a-2 : Decitabine (20mg/m2) | MEDICAL ONCOLOGY | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 |
CM0954-iii-b : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
CM0955 : Multiple Myeloma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0955-a : Lenalidomide (28 days) + Dexamethasone | MEDICAL ONCOLOGY | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 |
CM0955-b : Lenalidomide (21 days) + Dexamethasone | MEDICAL ONCOLOGY | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 |
CM0955-c : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone | MEDICAL ONCOLOGY | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 |
CM0955-e : Bendamustine | MEDICAL ONCOLOGY | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 |
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone | MEDICAL ONCOLOGY | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 |
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) | MEDICAL ONCOLOGY | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 |
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) | MEDICAL ONCOLOGY | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 |
CM0955-i : High-dose Cyclophosphamide | MEDICAL ONCOLOGY | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 |
CM0955-j : VAD / VAMP | MEDICAL ONCOLOGY | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 |
CM0955-k : Melphalan | MEDICAL ONCOLOGY | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 |
CM0955-l : Melphalan + Prednisolone | MEDICAL ONCOLOGY | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 |
CM0955-m : Thalidomide + Dexamethasone | MEDICAL ONCOLOGY | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 |
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) | MEDICAL ONCOLOGY | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 |
CM0956 : ALL LYMPHOMA SALVAGE CHEMO (Package 953 to be utilised) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0957 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (Package 953 to be utilised) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CM0100-N : BREAST CANCER - TAMOXIFEN | MEDICAL ONCOLOGY | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS | MEDICAL ONCOLOGY | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 |
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
CM0124-C : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
CM0955-O : Multiple Myeloma - Zoledronic Acid | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |